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Summary Intrinsic low-level resistance to anti-cancer drugs is a major problem in the treatment of gastrointestinal malignancies. To address
the problem presented by intrinsically resistant tumours, we have isolated two monoclonal lines from LoVo human colon adenocarcinoma
cells: LoVo/C7, which is intrinsically resistant to doxorubicin (DOX); and LoVo/C5, which shows the same resistance index for DOX as the
mixed parental cell population. For comparison, we have included in the study a LoVo-resistant line selected by continuous exposure to DOX
and expressing a typical multidrug resistant (MDR) phenotype. In these cell lines we have studied the expression and/or activity of a number
of proteins, including P-glycoprotein 170 (P-gp), multidrug resistance-associated protein (MRP), lung resistance-related protein (LRP),
glutathione (GSH)-dependent enzymes and protein kinase C (PKC) isoforms, which have been implicated in anti-cancer drug resistance.
Intracellular DOX distribution has been assessed by confocal microscopy. The results of the present study indicate that resistance in LoVo/C7
cells cannot be attributed to alterations in P-gp, LRP or GSH/GSH-dependent enzyme levels. Increased expression of MRP, accompanied by
alterations in the subcellular distribution of DOX, has been observed in LoVo/C7 cells; changes in PKC isoform pattern have been detected in
both intrinsically and pharmacologically resistant cells.
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resistance-related protein
The frequent occurrence of resistance to anti-cancer drugs is a
major problem in the treatment of gastrointestinal malignancies.
Two forms of drug resistance can be distinguished: tumour cells
are initially insensitive to chemotherapy (intrinsic or de novo
resistance) or they become insensitive after an initial response
following selection by the agent used for treatment (acquired
resistance). The multidrug resistant (MDR) phenotype, which is
frequently observed in cultured tumour cells exposed to anti-
neoplastic agents, is a typical example of acquired resistance,
involving a lack of response to a host of chemotherapeutic agents
and thereby drastically limiting the efficacy of pharmacological
interventions. An impressive body of experimental evidence has
accumulated over the past decade concerning the mechanisms
underlying the development of MDR. Overexpression of P-glyco-
protein 170 (P-gp), a membrane transporter for lipophilic xenobi-
otics, has been identified as a common occurrence in many MDR
cell lines (Gottesman and Pastan, 1993), although a number of
alternative or additional mechanisms have been described (Beck
et al, 1987; Cole et al, 1992; Scheper et al, 1993). However, the
MDR phenomenon largely depends on the experimental set-up,
and it is still unclear how relevant it might be to the clinic. In
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contrast, very few studies have addressed the problem presented
by intrinsically resistant tumours, which include some ofthe most
frequently lethal malignancies (colorectal and lung cancers) (Dong
et al, 1992). As a consequence, the mechanisms responsible for
intrinsic drug resistance and its correlation with the MDR pheno-
type remain largely to be established.
A major stumbling block in in vitro resistance studies is the fact
that most available tumour cell lines are in fact mixed populations,
with heterogeneous genetic patterns and variable chemosensi-
tivity. To overcome this difficulty, we have isolated a series of
sublines from LoVo human colon adenocarcinoma cells and from
this series we have selected two clones: LoVo/C7, which is intrin-
sically resistant to doxorubicin (DOX), and LoVo/C5, which
exhibits the same degree ofresponse to DOX as the mixed parental
cell population (LoVo/WT). In these two clones we have studied,
using biochemical and immunocytochemical techniques, the role
played by a number of proteins, including P-gp, MRP (multidrug
resistance-associated protein), LRP (lung resistance-related
protein) and glutathione (GSH)-dependent enzymes, in deter-
mining the intrinsically resistant phenotype of LoVo/C7 cells.
Intracellular DOX distribution has been assessed by confocal
microscopy. In addition, based on preliminary results obtained on
these cell lines (Dolfini et al, 1993), a detailed study of protein
kinase C (PKC) isoforms was performed. For comparison, we
have included in the study a LoVo-resistant line selected by contin-
uous exposure to DOX and expressing a typical MDR phenotype
(LoVo/DX) (Grandi et al, 1986). The results of the present study
show that the resistant phenotype observed in LoVo/C7 cells
cannot be attributed to alterations of P-glycoprotein, LRP or
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GSH/GSH-dependent enzyme levels. Increased expression of
MRP, accompanied by alterations in the subcellular distribution of
DOX, has been observed in LoVo/C7 cells; changes in PKC
isoform pattern have been detected in both intrinsically and
pharmacologically resistant cells.
MATERIAL AND METHODS
Cell lines
Two clones (LoVo/C5 and LoVo/C7) were isolated from the
human wild-type LoVo colocarcinoma cell line, as detailed else-
where (Dolfini et al, 1993) and were subsequently grown in vitro
in Ham's F12 medium supplemented with 10% fetal bovine serum
and vitamins (Mascia Brunelli, Milan, Italy) and maintained at
37°C in a 5% carbon dioxide atmosphere. The LoVo/DX cells
were obtained by exposure to increasing concentrations ofdoxoru-
bicin and maintained under the same culture conditions (Grandi et
al, 1986).
Cytotoxicity studies
Growth inhibition by DOX, etoposide (VP-16), melphalan (L-
PAM), vincristine (VCR) and camptothecin (CPT) was determined
by the MTT assay (Alley et al, 1988). Approximately 3000-5000
cells per well were plated onto 96-well plates (Nunc, Denmark)
and allowed to attach for 24 h before treatment with a range of
drug concentrations for 5 days. A 5-day exposure time was chosen
to allow the cells to grow in the presence of the drug for at least
two doubling times. Doubling times ranged from 27 h 42 min for
LoVo/WT to 57 h 15 min for LoVo/DX; initial cell densities were
adjusted accordingly to obtain a 80-90% confluent monolayer in
control wells at the end of the experiment. VP-16 and CPT stock
solutions were prepared in dimethyl sulphoxide (DMSO) and
subsequently diluted in complete tissue culture medium (final
DMSO concentration < 1% v/v); L-PAM was dissolved in a
minimal volume of perchloric acid and then diluted in medium to
the appropriate concentration.
Enzyme assays
Subconfluent cell monolayers were harvested with EDTA, washed
three times with phosphate-buffered saline (PBS), resuspended at
107 cells ml' in phosphate buffer and sonicated. The supematants
obtained by centrifugation ofcell sonicates at 30 000 g were used
to determine intracellular GSH levels and GSH-related enzyme
activities. Selenium-dependent GSH peroxidase (GSHpx) activity
was measured using the method described by Paglia and Valentine
Table 1 Cytotoxic effects of different antineoplastic agents on LoVo human
colon adenocarcinoma cell lines expressed as IC50 values obtained in a 5-
day MTT assay
LoVo/C5 (RI)a LoVo/C7 (RI)a LoVo/DX (RI)a
Doxorubicin 20.1 nm (1) 37.7 nM (1.88) 1.3 gM (64.03)
Etoposide 0.4 gM (1) 0.5gM (1.43) 25.4 gM (71.06)
Melphalan 9.0 gM (1) 6.8gM (0.76) 3.6gM (0.40)
Vincristine 2.5 nM (1) 4.8 nm (1.95) 0.8gM (321)
Camptothecin 52.2 nM (1) 45.8 nM (0.88) 14.7 nm (0.28)
aRI, resistance index relative to LoVo/C5.
(1967), using 73 gm hydrogen peroxide as a substrate. Glutathione
S-aryltransferase (GST) activity was determined by monitoring
the formation of GSH-adducts with 1-chloro-2,4-dinitrobenzene
(CDNB), according to the method described by Habig (1974).
Protein concentration was measured using the Coomassie blue
method as described by Bradford (1976). Total GSH levels were
evaluated by the kinetic assay described by Tietze (1969) in
perchloric acid-deproteinized samples. The data were analysed by
means of the analysis of variance; multiple comparisons were
evaluated by means ofScheffe's multiple range test (P-level 0.05).
Western blot analysis of whole cell lysates
Cells were grown to subconfluence in 75-cm2 flasks and
trypsinized. Cell suspensions were washed in PBS and resus-
pended in 20 pl of lysis buffer (10 mM Tris, pH 7.5; 1 mM EDTA;
1 mm phenylmethylsulphonylfluoride; 10 jg ml-' leupeptin, 1%
Triton X-100) per 106 cells. Cells were then sonicated for 8 s and
the material centrifuged in an Eppendorff microtube centrifuge at
maximum speed for 20 min. After assessing the protein content
using the BCA assay (Pierce Europe, The Netherlands) (Smith et
al, 1985), supematants were mixed with Laemmli sample buffer
and boiled. Fifty micrograms of protein for each sample were
loaded on a 10% polyacrylamide gel and electrophoresed. Proteins
were transferred onto nitrocellulose membranes and incubated for
I h with 5% non-fat dry milk. Blots were exposed to isoform-
specific rabbit polyclonal antibodies (Boehringer Mannheim,
Italy), diluted according to the manufacturer's instructions for 1 h
and then washed in PBS. To visualize immunoreactive bands, a
chemiluminescence kit (Boehringer Mannheim, Italy) was used,
following the manufacturers' protocols.
Flow cytometry
Time course accumulation studies were performed by flow cytom-
etry on LoVo/C5, LoVo/C7 and LoVo/DX cells treated with DOX
for up to 3 h. After treatment with 2,M or 10 ,UM DOX, cells were
washed with ice-cold Hank's balanced salt solution (HBSS),
detached with EDTA and trypsin and resuspended in ice-cold PBS.
For efflux studies, after washing with HBSS cells were incubated
in drug-free medium at 37°C up to 4 h. They were then analysed
on a FACScan flow cytometer (Becton Dickinson, Mountain
View, CA, USA) equipped with a 15 mW, 488 nm, air-cooled
argon ion laser. Fluorescence emission was collected after passing
through a 585 nm bandpass filter.
For determination of surface expression of P-glycoprotein, cell
suspensions were incubated for 30 min at 4°C with the monoclonal
antibody MM.4.17 (10 jg ml-') (Cianfriglia et al, 1994). After
washing with ice-cold PBS containing 10 mm sodium azide, 0.1%
bouine serum albumin (BSA) and 0.02% EDTA, cells were incu-
bated for 30 min at 4°C with 1:50 FITC-conjugated goat anti-
mouse IgG (Sigma Chemical, St Louis, MO, USA); after several
washings, cells were immediately analysed. Cells incubated with
the second antibody only were used as negative controls.
Laser scanning confocal microscopy (LSCM)
The intracellular distribution of DOX in different LoVo cell lines
was studied by laser scanning confocal microscopy (LSCM).
These studies were performed on living cells, grown on coverslips
and mounted on glass microscope slides in the presence of the
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Figure 1 Determination of glutathione levels (A), selenium-dependent
glutathione peroxidase (B) and glutathione-S-transferase in LoVo cell
lines. Values are the means ±s.d. of four independent experiments.
*P < 0.05 vs LoVo/C5
growth medium. In order to avoid cell damage, image acquisitions
were quickly performed on several cells per sample, acquiring
signals coming from one field per coverslip. The observations
were carried out with a Molecular Dynamics Sarastro 2000 CSLM
(Molecular Dynamics, Sunnyvale, CA, USA) equipped with a 25-
mW argon laser coupled to an epifluorescence Nikon Optiphot
microscope with a 60x oil-immersion objective lens (NA=1.4).
The 488-nm excitation filter, 510-nm primary dichroic beam-
splitter and 510-nm detector filter were used. Images were
acquired in average accumulation mode, with an image size of
1024x1024 pixels and pixel sizes of 0.08 p.m. The optical
sectioning was carried out with a 0.9-gm step size. Images were
stored andprocessed with a Silicon Graphics Computer. In order to
visualize both surface and internal structures, look-through projec-
tion processing was performed. This method allows the summa-
rizing of voxel intensities along projection rays - the rays lie
perpendicular to the plane of the sample. Acquisitions were
recorded using the pseudocolour intensity representation.
Immunocytochemical staining
P-gp expression was investigated by immunocytochemistry using
the avidin-biotin complex method with the monoclonal antibody
(MAb) JSB-1, which reacts against an internal epitope of P-gp
(Scheper et al, 1988). For MRP expression, the mouse MAb
MRPm6 (IgGl) was used. It was obtained after immunization
with a fusion protein containing amino acids 1294-1430 plus
1497-1531 of the MRP protein (Flens et al, 1994). MRPm6 has
been extensively characterized by protein blot analysis, immuno-
cytochemical and immunohistochemical studies, and it does not
cross-react with human P-gps (Flens et al, 1994). For LRP expres-
sion, the mouse MAb LRP-56 (IgG2b) was used. LRP-56 was
raised by immunization with the non-P-gp MDR lung cancer cell
line SW-1573/2R120, and it has been well characterized by
immunoprecipitation and immunocytochemical analysis. LRP-56
specifically recognized a 1 0-kDa protein (LRP) overexpressed in
a number ofnon-P-gp MDR cancer cell lines (Scheper et al, 1993;
Scheffer et al, 1995). Immunocytochemistry was performed on
unfixed cytospin preparations. Slides were incubated with normal
rabbit serum for 15 min and then with MRPm6 1:10 or LRP-56
1:500 for 1 h. Rabbit anti-mouse biotin conjugate (1:150 for
30 min; Zymed Laboratories, San Francisco, CA, USA) and
horseradish-streptavidin (1:500 for 1 h; Zymed) were the
second and third steps respectively. Amino-ethylcarbazole (ICN
Biochemicals, Aurora, OH USA) was used as a chromogen. Slides
were counterstained with haematoxylin. Negative control slides
were treated as above, substituting the primary antibody with an
irrelevant IgG or PBS. GLC4S and GLC4/DOX cells, and SW-
1573 and SW-1573/2R120 cells served as controls for MRP and
LRP expression respectively (Scheper et al, 1993; Flens et al,
1994). Evaluation was done on coded slides to avoid bias in
scoring cell lines.
RESULTS
Cytotoxicity studies
Table 1 shows the effects ofDOX, VP-16, L-PAM, VCR and CPT
expressed as the IC50 values obtained after 5-day exposure to the
drugs. LoVo/DX cells exhibited a marked cross-resistance to
DOX, VP-16 and VCR, as expected from a P-gp expressing cell
line; however, these cells showed a slight increase in their sensi-
tivity to L-PAM and CPT compared with the two clonal lines.
GSH and GSH-dependent enzymes
No significant differences in GSH levels (Figure IA) and
Selenium-dependent GSHpx activity (Figure 1B) were detected
among the three LoVo cell lines tested. In contrast, a slight but
significant decrease in GST activity was observed in LoVo/C7
cells compared with the two other cell lines, which had similar
values for this enzyme (Figure IC).
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Figure 2 Western blot analysis of PKC isoforms in LoVo cells
Analysis of PKC isoforms
Of the tested PKC isoenzymes, a-, 6-, e- and 4-isoforms were
detectable in the three cell lines, although some differences in
expression were apparent. In fact, while 6- and 4-PKC protein
levels were similar in all cell lines, marked differences were
observed in a- and s-PKC expression: higher levels of the a-
isoform were found in both LoVo/DX and LoVo/C7 cells
compared with LoVo/C5 cells, whereas e-PKC was markedly
decreased in both resistant lines, particularly in LoVo/C7 cells
(Figure 2). In contrast, 3-PKC was found to be barely detectable in
these cell lines by a preliminary test and therefore was not
analysed further.
Flow cytometry
Flow cytometric determination of surface P-glycoprotein expres-
sion showed that only LoVo/DX cells were positive for MM.4.17
labelling, while the clonal lines LoVo/C5 and LoVo/C7 did not
show any reactivity with this antibody (Figure 3)
Figure 4 shows the time course ofdrug accumulation (up to 3 h)
and efflux (up to 4 h) in cells treated with 2 ,UM and 10 ,UM DOX
(Figure 4A and B respectively). When the lower dose was used, no
significant difference in intracellular fluorescence was observed
between LoVo/C5 and LoVo/C7 cells; however, when cells were
treated with 10 ,UM DOX, LoVo/C5 cells seemed to accumulate a
higher drug amount than LoVo/C7. In any case, a very low drug
uptake was detected in LoVo/DX cells. When the cells were
allowed to recover in drug-free medium for 4 h LoVo/DX cells
showed a complete efflux of the drug, while in the other lines the
efficiency of extrusion of the drug was much lower. However, a
small difference in efflux rate can be observed between LoVo/C5
and LoVo/C7 cells, efflux being significantly faster in the latter.
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Figure 3 Flow cytometric analysis of cell surface P-glycoprotein is indicated
by the fluorescence intensity (on the abscissa) of the antibodies bound to
the cells. The MDR variants of LoVo cells (LoVo/DX) appeared to be positive
for Mab MM4.17 (right curve in A). The two clones LoVo/C5 and LoVo/C7
(B and C) did not show significant reactivity against this antibody
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Figure 4 Flow cytometric analysis of the time course of doxorubicin accumulation and efflux in LoVo cells treated with doxorubicin 2FkM (A) or 10 JIM (B) for 3 h
and then recovered in drug-free medium for 4 h. Each data point is the mean ± s.e. of three independent experiments. 0, LoVo/C5;@*, LoVo/07; O, LoVo/DX
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Figure 5 Intracellular distribution of DOX in living LoVo cells detected by laserscanning confocal microscopic determination of (A) LoVo/C5 and (B) LoVo/C7
treated with 2 gM DOX for 1 h, (C) LoVo/C5 and (D) LoVo/C7 cells treated with 10 gm DOX for 1 h, (E and F) LoVo/DX cells treated with 2gM DOX for 1 h and
10gM DOX for 24 h respectively. Bar = 30 gm
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Figure 6 Immunocytochemical staining for MRP (with the mouse MAb MRPm6, left-hand column) and for LRP (with the mouse Mab LRP-56, right-hand
column) in LoVo/C5 (A and B), LoVo/C7 (C and D) and LoVo/DX cells (E and F). Bar = 50 gm
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Table 2 Immunocytochemical staining of LoVo human colon carcinoma cell
lines
Protein (MAb) LoVo/C5 LoVo/C7 LoVo/DX
( /±/+/++)a (_/±/+/++) (_/±/+/+ l)
P-gp (JSB-1) 20/75/5/0 5/90/5/0 0/20/75/5
MRP (MRPm6) 50/50/0/0 0/50/50/0 40/55/5/0
LRP (LRP56) 98/2/0/0 95/5/0/0 0/0/20/80
aStaining intensity for each cell line was determined according to the following
scale: no staining, -; weak, ±; positive, +; strong, ++. Percentages of staining
were determined by counting at least 200 cells per preparation.
Laser scanning confocal microscopy
Exploiting the intrinsic fluorescence of anthracycline antibiotics,
the intracellular distribution of DOX was analysed by LSCM in
LoVo clonal lines, comparing it with the drug distribution
observed in the pharmacologically induced resistant cells.
LoVo/C5 and LoVo/C7 cells showed a different intracellular
distribution of DOX. After treatment with 2 gM DOX for 1 h, the
drug appeared to be exclusively localized in the nuclei (Figure SA
and B) in both cell lines. Nuclei became strongly fluorescent in
LoVo/C5 cells after incubation with 10 gM for 1 h (Figure SC). In
LoVo/C7 cells treated with 10gM DOX the drug was shown to be
distributed both in the nucleus and the cytoplasm, which appeared
weakly positive (Figure 5D). Pharmacologically resistant
LoVo/DX cells treated with 2gM DOX for 1 h showed anegligible
fluorescent signal (Figure SE). In order to detect a significant
DOX signal, resistant cells were treated with the higher dose of
DOX for 24 h (Figure SF). In this case, the drug was localized
exclusively in the cytoplasm, whereas the nuclei appeared to be
always negative.
Immunocytochemical staining for P-gp, MRP and LRP
The staining results on the panel of LoVo colon carcinoma cell
lines are shown in Figure 6 and summarized in Table 2. A small
but distinct increase in MRP expression was noticed in LoVo/C7
cells (Figure 6C) compared with its non-resistant counterpart
LoVo/CS (Figure 6A). In contrast, neither clonal line showed any
evidence for increased LRP (Figure 6B) for LoVo/CS and 6D for
LoVo/C7). In LoVo/DX cells, MRP staining was mostly negative
(Figure 6E), whereas a marked increase in LRP staining could be
observed (Figure 6F). Staining for P-gp with the JSB-1 MAb
(Table 2) confirmed that LoVo/DX cells highly overexpress this
glycoprotein; neither LoVo/C5 norLoVo/C7 cells exhibited signif-
icant levels ofP-gp expression.
DISCUSSION
Low-level spontaneous resistance to anti-cancer agents is a
frequent occurrence in the clinical management of a number of
common malignancies. Lack of suitable experimental models is
a major drawback in the study of the mechanisms responsible
for intrinsic resistance in colorectal cancer cells. The present
study was aimed at the characterization of a LoVo human colon
adenocarcinoma cell clone that exhibits low-level spontaneous
resistance to DOX (LoVo/C7).
The first step in our characterization ofLoVo/C7 cells was to test
whether they were also cross-resistant to other chemotherapeutic
agents. In a5-day MTTcytotoxicity assay, LoVo/C7 cells displayed
low-level cross-resistance to VP-16 and VCR compared with
LoVo/C5 cells, whereas no differences were observed between the
two clonal lines regarding L-PAM and camptothecin. This pattern
suggests a typical form ofMDR; however, no P-gp overexpression
was detected in LoVo/C7 cells, both by Northern blot analysis
(Conforti et al, 1995) and according to the immunocytochemical
and confocal microscopic datapresented in this paper. As expected,
LoVo/DX cells expressed significant levels ofP-gp and were found
to be highly cross-resistant to VP-16 and VCR.
Other membrane proteins besides P-gp have been implicated in
the development of anti-cancer drug resistance and, in the present
study, we have focused our attention on LRP and MRP. LRP was
first identified in a MDR lung cancer cell line (Scheper et al,
1993); cloning and sequencing ofthe LRP gene indicated LRP as
the human homologue ofthe rat major vaultprotein (Scheffer etal,
1995). Vaults have been described as ribonucleoprotein particles,
the majority ofwhich can be found in the cytoplasm, while a small
fraction are localized to the nuclear membrane where they are
hypothesized to interact with or be part of the nuclear pore
complex (Rome et al, 1991). The observed subcellular distribution
suggests that they may be implicated in the bidirectional transport
of a variety of substrates and/or their cytoplasmic redistribution
andhighlights apossible role ofthese organelles inmediating drug
resistance (Izquierdo et al, 1996). However, LRP does not seem to
play a major role in determining the intrinsically resistant pheno-
type in LoVo/C7 cells. In fact, ourimmunocytochemical data indi-
cate that LRP expression is not altered in LoVo/C7 cells, whereas
an increase in this protein can be observed in LoVo/DX cells. In
contrast, we have found that MRP expression is increased in
LoVo/C7 cells (but not in LoVo/DX cells). MRP is another
membrane carrier associated with the MDR phenotype, which was
first identified by Cole et al (1992) in the small-cell lung carci-
noma (SCLC) cell line H69 and since then has been described in a
number of multidrug-resistant, non-P-gp-expressing cell lines
(Krishnamachary and Center, 1993; Schneider etal, 1994; Eijdems
et al, 1995; Versantvoort et al, 1995a). The range of chemothera-
peutic drugs involved in MRP-mediated multidrug resistance
broadly overlaps that observed for P-gp, including anthracyclines,
epipodophyllotoxins and Vinca alkaloids (Grant et al, 1994;
Zaman et al, 1994). The degree of resistance observed in MRP-
expressing cells is generally lower than in cells overexpressing
P-gp (Eijdems et al, 1995). In DOX-resistant HL-60 cells, a non-
P-gp-expressing human promyelocytic leukaemia cell line, MRP
was identified primarily in the endoplasmic reticulum, with lower
levels also present in the plasma membrane (Marquardt and
Center, 1992; Krishnamachary and Center, 1993), whereas a
predominant function as a plasma membrane efflux pump has
been demonstrated in a SCLC and in a non-small-cell lung carci-
noma (NSCLC) cell line selected by exposure to DOX (Zaman et
al, 1994). In either case, MRP overexpression seemed to lead to a
reduced drug access to its intracellular target, by increasing drug
efflux and/or by altering its intracellular distribution. Increased
MRP expression in LoVo/C7 cells, compared with the normo-
sensitive clone, could account for the low-level cross-resistance
observed upon exposure to VP-16 and VCR and could also
provide an explanation for the lowerdegree ofDOX accumulation
and for the altered pattern of intracellular drug distribution
observed when cells were treated with 10gM DOX.
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In the present study, an additional possible mechanism for the
intrinsically resistant phenotype of LoVo/C7 cells has been exam-
ined, namely alterations of PKC isoform pattern. Increases in
overall PKC expression and/or activity have been demonstrated to
correlate with a MDR phenotype in a number of cell lines (Fine
et al, 1988; O'Brian et al, 1989; Dong et al, 1991; Chaudary and
Roninson, 1992; Gollapudi et al, 1992), with the Ca2+-dependent
isoform oc-PKC specifically implicated in this phenomenon (Yu
et al, 1991; Ahmad and Glazer, 1993). In a preliminary report, we
analysed the role of Ca2+-dependent PKC isoforms in LoVo/C7
cells and our findings suggested a contribution of oc-PKC to the
intrinsically resistant phenotype (Dolfini et al, 1993). In the present
study, we have extended the panel of PKC isoforms studied. The
results we obtained with ax-PKC confirm those of our previous
report (increased expression in LoVo/C7 and LoVo/DX cells); a
parallel decrease in e-PKC levels has also been observed in
LoVo/C7 and LoVo/DX cells. Similar instances of inverse regula-
tion of calcium-dependent and -independent PKC isoforms have
been reported for human breast and cervix carcinoma cell lines and
their multidrug-resistant variants, but it is not clear how this effect
correlates with the resistant phenotype (Blobe et al, 1993; Drew et
al, 1994; Davies et al, 1996). As to the substrates whose phospho-
rylation may be affected by these changes in PKC isoform pattern,
no unequivocal indication has emerged from the various studies on
this issue; P-gp has been shown to be phosphorylated by oc-PKC
(Davies et al, 1996), but the impact ofphosphorylation of P-gp on
its activation is still a matter of debate. (It is extremely unlikely to
play a major role in intrinsic resistance of LoVo/C7 cells anyway,
as P-gp expression is undetectable in these cells.) On the other
hand, recent reports indicate that MRP is also a substrate for PKC
(Gekeler et al, 1995; Ma et al, 1995), and the possibility that phos-
phorylation might positively modulate MRP activity could be more
relevant to the resistant phenotype ofLoVo/C7 cells. However, this
hypothesis awaits further experimental support.
In summary, we can conclude that the intrinsically resistant
clone isolated from LoVo cells is a suitable model for mechanistic
studies on this type of resistance, which has probably a great clin-
ical relevance even though the degree of resistance is moderate.
Our data suggest that intrinsic resistance to DOX in LoVo cells
depends largely on increased expression ofMRP and on the subse-
quent alteration in the subcellular localization of the drug.
Changes in PKC isoforms, both Ca2+ dependent and independent,
also seem to play a role, although further investigations are
required to identify the relevant substrates.
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